Takara Bio announces partnership for the distribution of CE-IVD solutions for respiratory tract infectionsSeptember 6, 2022
Takara Bio Europe (TBE) announced today a partnership with the German company BioeXsen GmbH for the distribution of in vitro diagnostic solutions for the qPCR detection of common pathogens found in respiratory tract infections.
Respiratory tract infections are associated with high morbidity and mortality worldwide, and their symptoms may not point to a single diagnosis. In such cases, a rapid and accurate pathogen diagnosis is essential for appropriate treatment.
BioeXsen has been one of the leading suppliers of RT-qPCR kits during the Covid-19 pandemic. The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes. Combining Takara Bio's renowned expertise in molecular biology with BioeXsen GmbH's state-of-the-art clinical solutions, the in vitro diagnostic medical devices detect more than 20 pathogens.
Ranging from the detection of the novel coronavirus (SARS-CoV-2) to multiplexed detection of 24 pathogens in a syndromic panel, these CE-IVD kits’ simple yet efficient protocols have been tested and validated on commonly used instruments and can accommodate a wide range of samples, with an optimized turnaround time of 29 to 60 minutes. These efficient and significant solutions have already been used for more than 200 million tests worldwide, proving their versatility and suitability for all laboratories.
“At Takara Bio, we strongly believe that high-performing technologies are the keystone to accurate diagnosis” says Pierre Lacaze, Managing Director at TBE. “Since the beginning of the Covid-19 pandemic, we have been committed to supplying robust enzymes and supporting our customers to develop and optimize their diagnostic solutions. We are proud to take another step forward in our partnership with BioeXsen GmbH to distribute a broad portfolio of vital in vitro diagnostic medical devices for infectious diseases.”
Klaus Skripalle, Managing Director of BioeXsen GmbH, added, "The synergistic combination of Takara Bio’s reliable enzymes and the cutting-edge technology here at BioeXsen GmbH will result in both higher specificity and increased sensitivity. This alliance provides us with enzymes of better calibre to our previous existing products, allowing us to increase our strength further, which is particularly pertinent at this critical time. As we have all learned during the pandemic, early diagnosis reduces the risk of hospitalization, decreases drug use, and minimizes the risk of death.”
With the distribution of these kits, Takara Bio Europe is proud to continue providing essential tools in the fight against COVID-19 and related diseases.
About Takara Bio Group
Takara Bio Europe
Takara Bio Europe is a wholly owned subsidiary of Takara Bio Inc., which develops, manufactures, and distributes a wide range of life science reagents under the Takara™, Clontech®, and Cellartis® brands.
Takara Bio’s portfolio supports applications including NGS, gene discovery, regulation, and function studies, genetic analysis, protein expression and purification, gene editing, stem cell studies, and plant and food research. For more information, visit www.takarabio.com.
Takara Bio Inc.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin® reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. For more information, visit www.takara-bio.com.
About BioeXsen GmbH
BioeXsen GmbH is a biotechnology company focused on innovative molecular technologies, operating in the field of in vitro diagnostics. Founded in Germany, BioeXsen opened its doors to the world with its innovative and reliable technology and became one of the most substantial companies in the industry.
BioeXsen products are based on nucleic acid amplification technology (NAAT) and consist of complete solutions for a real-time polymerase chain reaction (qPCR), included with nucleic acid extraction reagents for sample preparation. BioeXsen also provides vNAT® Systems that inactivate viruses and release and preserve nucleic acids. qPCR kits are used in the in vitro detection of pathogens, allowing healthcare providers to identify infections and make critical decisions quickly. For more information, visit www.bioexsen.com.
Corporate, Finance & Investor